Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays.

Positron Emission Tomography of bromine-76 and yttrium-86 results in the detection of coincident events that are not strictly associated with annihilation photon pairs. Instead, these coincidences occur because prompt gamma rays emitted by these nuclides result in cascades of photons that are emitted within the timing window of the PET scanner. Pairs of detected photons from these cascades are not angularly correlated and therefore contain little information regarding the location of their source. Furthermore, these coincidences are not removed by correction procedures (e.g., randoms, scatter) routinely applied to PET data. If left uncorrected, the cascade coincidences will result in spurious apparent activity within the PET images. A correction, applied within projection space, that removes the cascade coincidence signal from septa-in (i.e., two-dimensional) datasets is proposed and tested on phantom data.

[1]  N. Hendrikse.  Monitoring interactions at ATP-dependent drug efflux pumps. , 2000, Current pharmaceutical design.

[2]  V. Grégoire,et al.  Use of 5-[76Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  K. Leenders,et al.  [76Br]Bromodeoxyuridine PET in tumor-bearing animals. , 2001, Nuclear medicine and biology.

[4]  Balraj Singh.  Nuclear data sheets update for A = 76 , 1995 .

[5]  M. M. King.  Nuclear Data Sheets for A = 86 , 1997 .

[6]  M. Lubberink,et al.  Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET. , 2002, Physics in medicine and biology.

[7]  M. Bergström,et al.  Distribution of (76)Br-labeled antisense oligonucleotides of different length determined ex vivo in rats. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  S. Walrand,et al.  Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86 , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  C. Bohm,et al.  Correction for Scattered Radiation in a Ring Detector Positron Camera by Integral Transformation of the Projections , 1983, Journal of computer assisted tomography.

[10]  H. Lundqvist,et al.  Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET. , 2000, Nuclear medicine and biology.

[11]  H. Herzog,et al.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.

[12]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[14]  M. Baulac,et al.  In vivo imaging of muscarinic cholinergic receptors in temporal lobe epilepsy with a new PET tracer: [76Br]4-bromodexetimide. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  A. Waki,et al.  Evaluation of [76Br]FBAU 3',5'-dibenzoate as a lipophilic prodrug for brain imaging. , 2002, Nuclear medicine and biology.

[16]  Larson,et al.  Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[17]  H. Lundqvist,et al.  PRODUCTION OF 76BR BY A LOW-ENERGY CYCLOTRON , 1998 .

[18]  J. Humm,et al.  PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels , 2001 .